Cognition outlines mid-2027 Phase III start in DLB and cash runway into Q4 2027

Cognition Therapeutics Q3 2026: FDA-aligned Phase III DLB trial plans, zervimesine catalyst timing, cash runway and funding risks.

CryptoAlerta — análise de criptomoedas e mercado em tempo real